# Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)

> **NCT04390113** · PHASE3 · TERMINATED · sponsor: **AlloVir** · enrollment: 97 (actual)

## Conditions studied

- BK Virus Infection
- Hemorrhagic Cystitis

## Interventions

- **BIOLOGICAL:** Posoleucel (ALVR105)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04390113
- **Lead sponsor:** AlloVir
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-18
- **Primary completion:** 2024-01-30
- **Final completion:** 2024-01-30
- **Target enrollment:** 97 (ACTUAL)
- **Why stopped:** Study discontinued as DSMB determined it was futile. No safety concerns were noted.
- **Last updated:** 2024-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04390113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04390113, "Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04390113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*